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Summary
PURPOSE: Chemotherapy (CT) combined with radiation
therapy (RT) is the standard treatment for limited disease
small-cell lung cancer (LDSCLC). Many questions includ-
ing RT dose, fractionation, and sequence of RT/CT ad-
ministration remain controversial. In this paper, we retro-
spectively assessed the outcome of patients with LDSCLC
treated with radiation of at least 50 Gy.
METHODS AND MATERIALS: From December 1997 to
January 2006, 69 consecutive patients with LDSCLC were
treated at our institutions. Treatment consisted of at least 4
cycles of CT, and 3D conformal thoracic RT. The median
age was 61 years (range, 37–78 years). Sequential or con-
comitant CT/RT was given in 47 (68%) and 22 (32%) of
the patients, respectively. The median RT dose was 60 Gy.
Prophylactic cranial irradiation (PCI) was administered in
47 (68%) patients.
RESULTS: With a median follow-up of 36 months (range,
6–107), 16 patients were alive without disease. The median
overall survival time was 24 months, with a 3-year survival
rate of 29%. The 3-year disease-free survival (DFS) and
loco-regional control (LRC) rates were 23% and 60%, re-
spectively. A better DFS was significantly associated with
performance status (PS) 0 (p = 0.004), complete response
to treatment (p = 0.03), and PCI group (p = 0.03). A trend
towards improved overall survival (OS) was observed for
patients who underwent PCI (p = 0.07). Patients treated
with sequential CT/RT had a better outcome than those
treated with concomitant treatment (3-year DFS rate 27%
vs. 13%; p = 0.04). However, PCI was delivered more fre-
quently for the sequential group. No significant dose-re-
sponse relationship was found in terms of LRC. The mul-
tivariate analysis showed that complete response to treat-
ment was the only significant factor for OS.
CONCLUSION: Complete response to treatment was the
most important factor for OS. A better DFS was signific-
antly associated with the PCI group. We did not find a sig-
nificant difference in outcome between patients receiving
doses of 60 Gy or more and patients receiving 60 Gy or
less.
Key words: Small-cell lung cancer; limited stage;
radiotherapy; combined modality treatment; sequential
chemotherapy
Introduction
Treatment strategies for small-cell lung cancer (SCLC)
have gradually evolved over the past few decades. In the
past, chemotherapy (CT) alone was considered the standard
therapy for patients with SCLC. However, the overall out-
come of patients has remained poor due to both local and
systemic relapses [1]. Chest radiotherapy (RT) in combina-
tion with CT has become a generally accepted treatment for
limited stage SCLC (LDSCLC), since it has been shown to
be superior to CT alone [2–3]. Moreover, the routine use
of prophylactic cranial irradiation (PCI) has contributed to
a reduction in the rate of brain recurrences, and to the im-
provement in overall survival [4]. During the same period,
strategies assessing more dose-intensive RT through hyper-
fractionation and/or concomitant platinum-based CT resul-
ted in a greater survival benefit [5, 6].
Although it is clear that chest RT improves both local con-
trol and survival [2–3], several important questions includ-
ing RT dose, RT fractionation, RT volume, timing of CT,
and RT/CT sequence of administration remain controver-
sial and unanswered. The local failure rate in the chest re-
mains unacceptably high with moderate RT doses. In the
study by Turrisi et al. [5], local failure at 5 years reached
75% with daily RT compared to 42% with twice daily RT.
In our institutions, RT doses have been increased progress-
ively since the late 1990s. This study aimed to evaluate the
outcome and patterns of failure in patients with LDSCLC
treated with radiation of at least 50 Gy in two institutions.
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Methods and materials
Patients
A retrospective study of 69 consecutive patients with
LDSCLC, treated between 1997 and 2006, was performed.
There were 23 (33%) women and 46 (67%) men. The me-
dian age was 60 years (range, 36–78 years). Most patients
had one or more symptoms. Dyspnea was the most com-
mon presenting symptom accounting for 35% (n = 24) of
presentations, followed by cough 17% (n = 12), chest pain
19% (n = 13), and superior vena cava obstruction 4% (n
= 3). Four patients (6%) were referred for incidental ab-
normal findings on chest radiographs, and seven patients
(10%) were found to have paraneoplastic syndromes, either
inappropriate anti-diuretic hormone syndrome or Lambert
Eaton syndrome.
Concurrent malignancy was found in 2 patients (3%): one
with in-operable rectal cancer treated with palliative stent-
ing, and the other with early breast cancer treated with
standard conservative treatment.
Upon referral, minimal diagnostic workup consisted of a
physical examination, bronchoscopy, complete blood
count, blood biochemistry and imaging studies. Besides
chest radiography, computed tomography of the chest and
upper abdomen, brain computed tomography or magnetic
resonance imaging (MRI), radionucleide bone scan and,
more recently, positron emission tomography (PET) were
done. A total of 23% of the patients underwent bone-mar-
row aspiration and nine patients (13%) underwent medi-
astinoscopy (n = 8) or mediastinostomy (n = 1). All patients
had biopsy-proven SCLC.
Patients were classified as limited-stage disease when their
tumour was confined to one hemithorax with or without
hilar, mediastinal or supraclavicular nodes, and treatable
within a single radiotherapy volume. All of the patients had
LDSCLC according to the 2002 UICC/AJCC classification
system for lung cancer [7, 8]. For patients treated before
2002, staging was updated from the clinical description to
fit the new classification. There were 7 (10%) T1, 25 (36%)
T2, 15 (22%) T3, and 22 (32%) T4 tumours. The N-clas-
sification included 2 (3%) patients with Nx, 8 (12%) pa-
tients with N0, 5 (7%) with N1, 37 (53%) with N2, and 17
(25%) with N3 disease. Patient characteristics are presen-
ted in table 1.
Treatment
Varied chemotherapy regimens were given because pa-
tients were referred from different oncologists. Patients
were treated with etoposide (100 mg/m² on days 1–3), and
either cisplatin (100 mg/m² on day 1; n = 25) or carboplat-
in (AUC 5; n = 16). In 4 patients, carboplatin was substitu-
ted for cisplatin because of clinically significant ototoxicity
or sensory neural damage. Etoposide and cisplatin (EP) or
carboplatin (CP) were combined with adriamycin (n = 4) or
paclitaxel (n = 1).
Table 1: Patient characteristics in 69 patients with small cell lung cancer.
Characteristics
Median age (yrs) 60 36–78
Median amount of smoking (packs per year) 50 20–120
N %
Gender
Male 46 66
Female 23 33
Performance status (WHO)
0 51 75
1 16 23
2 1 1
Not known 1 1
T-classification (UICC)
T1 7 10
T2 25 36
T3 15 22
T4 22 32
N-classification (UICC)
Nx 2 3
N0 8 12
N1 5 7
N2 37 53
N3 17 25
Chemotherapy
Sequential 47 68
Concomitant 22 32
Thoracic radiation
Median dose (Gy) 60 20–66
Median dose/fraction (Gy) 1.8 1.5–2
PCI use
Yes 47 68
No 22 32
Abbreviation: UICC: Union Internationale Contre le Cancer; WHO: World Health Organisation; PCI: prophylactic cranial irradiation
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Ten patients received the ICE regimen, which consisted of
ifosfamide (5 g/m², day 1), carboplatin (300 mg/², day 1)
and etoposide (180 mg/m², day 1–2). Nine other patients
were treated with induction chemotherapy using epirubicin
and paclitaxel followed by intensification with a ifosfamide
(2.5 g/m2 day 1–4), carboplatin (AUC 5, day 1–4) and
etoposide (300 mg/m2, day 1–4) regimen, with mesna fol-
lowed by autologous stem cell infusion. At least 4 cycles
(median, 6) of chemotherapy were given, each cycle separ-
ated by 21–28 days.
A total of 22 patients (32%) received RT concurrently with
chemotherapy, and 47 (68%) received RT sequentially to
chemotherapy. The sequential RT was used when tumours
were so large that concurrent chemo-radiotherapy was con-
sidered to carry a high risk of severe radiation pneumon-
itis. Consolidating thoracic 3-dimensional conformal RT
was given to all patients. Megavoltage equipment was used
with energies varying from 6 to 18 MV. RT was delivered
to the primary tumour, ipsilateral hilum, and mediastinal
lymph nodes to a dose of 40 Gy in daily fractions of
1.8–2 Gy using mainly parallel opposed antero-posterior
and postero-anterior fields (n = 59), or 3 fields (n = 8). The
supraclavicular region was included only when involved.
Oblique off-cord fields, including the site of primary tu-
mour and involved lymph nodes, were used for the remain-
ing treatment course. The dose of RT delivered to the lung
was limited to 35% of the volume receiving no more than
20 Gy. The spinal cord dose was limited to 45 Gy. The
majority of patients were treated with a daily fractiona-
tion of 1.8–2 Gy. The treatment was administered twice
daily in 5 patients (1.5 Gy per fraction, with 6 hours or
more between fractions). The median total dose was 60 Gy
(range, 20–66 Gy). The median overall treatment time was
42 days (range, 22–64).
Following treatment, 47 patients (68%) also received a pro-
phylactic cranial irradiation (PCI) delivered by lateral op-
posing fields using 6–18 MV photons. This treatment was
proposed to all patients without any progressive disease.
Five patients refused the treatment, one had progressive
disease and in 16 patients the reason for not doing PCI was
unknown. The median total dose was 30 Gy (range, 26–38)
in daily 1.8–2 Gy fractions.
Definition of response
The initial tumour response was based on CT scans follow-
ing completion of the treatment. Complete response (CR)
was defined as the complete disappearance of all objective
evidence. Near complete response (near-CR) was defined
as a greater than 90% reduction in the maximum diamet-
er of the tumour with persistent scanographic abnormalit-
ies. Partial response (PR) was defined as regression of 50%
or more of the tumour,, and progressive disease (PD) was
defined as an increase of at least 25% of the tumour. Distri-
bution of the treatment characteristics by treatment arm, se-
quential RT versus concomitant RT, are presented in table
2. After completion of the treatment, patients were seen for
response and toxicity testing every 3 months for the first 2
years, every 6 months until 5 years, and yearly thereafter. A
computed tomography scan of the chest was obtained every
6 months for 2 years, and yearly for the following 3 years.
Statistical analysis
Mean values were compared by the Student’s t-test. Pro-
portions were compared using the chi-square test for values
greater than 5, and Fisher’s exact test for those less than
or equal to 5. Kaplan-Meier product-limit estimates were
used to evaluate overall survival (OS), disease-free survival
(DFS), and loco-regional control (LRC) (9). Univariate
analyses included all variables thought to be influencing
the outcome (age, gender, World Health Organisation
(WHO) performance status (PS), T- and N-classification,
timing of RT, PCI use, treatment response, and thoracic RT
dose). Multivariate analysis (Cox Model) included WHO
PS, timing of RT, PCI use, treatment response, and thoracic
RT dose. Time to any event was measured from the date of
pathological diagnosis. The events were death (all causes
of death included) for OS, death or any relapse for DFS,
and loco-regional relapse for LRC (patients who died
without local or loco-regional relapse were censored at
the time of death), respectively. Confidence intervals (CI)
were calculated from standard errors. Differences between
groups were assessed using the log-rank test [10]. The Bon-
ferroni method was used to adjust the individual p-values in
order to obtain overall significance levels depending on the
number of parameters tested (p-adjusted equals individual
p-value times number of parameters tested) [11].
Results
With a median follow-up of 36 months (range, 6–107
months), 16 (23%) of the 69 patients remained alive
Table 2: Distribution of treatment characteristics by treatment arm-sequential (S; n = 47) versus concomitant(C; n = 22) CT/RT.
Characteristics S (%) C (%)
Type of chemotherapy
EP/Carboplatin-Etoposide 25 (53) 20 (90)
ICE 19 (41) 0
Others 3 (6) 2 (10)
PCI use
Yes 35 (75) 12 (54)
No 12 (25) 10 (46)
Response to treatment*
CR 10 (21) 9 (41)
nCR 13 (28) 4 (18)
PR 23 (49) 7 (32)
Abbreviation: CT/RT: chemo-radiotherapy; EP: etoposide-cisplatin; ICE: ifosfamide, carboplatin, etoposide; PCI: prophylactic cranial irradiation; CR: complete response;
nCR: near complete response; PR: partial response; *data missing in 3 patients.
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without disease. Causes of death included SCLC in 48, and
treatment-related toxicity in 2 patients.
Figure 1
Kaplan-Meier curves for overall survival (OS, solid line; DFS, dotted
line; and LRC, dashed line) in 69 patients with limited stage small-
cell lung cancer.
Figure 2
Disease-free survival according to sequential (solid line, n = 47)
versus concomitant (dotted line, n = 22) chemotherapy in 69
patients with limited stage small-cell lung cancer (log rank test, p =
0.02).
Figure 3
Loco-regional control rate according to sequential (solid line, n =
47) versus concomitant (dotted line, n = 22) chemotherapy in 69
patients with limited stage small-cell lung cancer (log rank test, p =
0.04).
Patterns of Failure
Among all patients, 19 (29%), 30 (45%), and 17 (26%) pa-
tients achieved a CR, a near-CR and a PR, respectively.
Three patients progressed during treatment. Of the 69 pa-
tients, 22 had chest failure (31%), and 36 patients (52%)
developed distant metastases at one or more sites. Brain re-
lapse was identified in 17 patients (24%), of whom 9 had
received PCI. Twelve (17%) patients relapsed only in the
brain, including 5 patients after PCI. Other sites of meta-
stases were the liver (n = 8), bone (n = 7), adrenals (n = 7),
and retroperitoneal lymph nodes (n = 4).
The median OS for all patients was 24 months. The 3-year
OS, DFS and LRC rates for all 69 patients were 29% (95%
CI, 18–40%), 23% (95% CI, 13–33%), and 60% (95% CI,
47–73%), respectively (fig. 1).
We examined the effect of various factors on OS in univari-
ate analyses (table 3), including age, gender, WHO PS, T-
and N-classification, timing of RT, PCI use, treatment re-
sponse, and thoracic RT dose. Response to treatment was
the only significant factor (p = 0.04) for overall survival.
Patients with CR had better outcomes than patients with
PR (35% vs 16%). Although not statistically significant,
sequential chemo-radiotherapy appeared to be superior to
concomitant chemo-radiotherapy. At 3 years, patients in
the sequential group had an OS rating of 32%, whereas pa-
tients in the concomitant group had a 22% rating (p = 0.21).
Likewise, a trend toward improved survival was observed
for patients with a good PS (p = 0.06) and in patients re-
ceiving PCI (p = 0.07). The 3-year OS was 35% (95% CI,
21–49%) for patients who underwent PCI compared with
17% (95% CI, 0–34%) for those not receiving PCI. The
multivariate analysis showed that improved survival was
associated with a complete response to treatment (relative
risk (RR = 3.39; p = 0.04).
In the univariate analysis, better DFS was significantly as-
sociated with the timing of RT, performance status 0, PCI
group and complete response to treatment, but no effect
was seen with age, gender, thoracic RT dose, or T and N
classification (table 3). The use of sequential CT/RT cor-
related significantly with DFS. The 3-year DFS rate was
27% (95% CI, 15–39%) for those receiving sequential CT/
RT, and 13% (95% CI, 0–28%) for those receiving the con-
comitant RT (p = 0.04; fig. 2). A better DFS was signific-
antly associated with PS 0 (p = 0.004), complete response
to treatment (p = 0.03), and PCI group (p = 0.03). The
3-year DFS was 27% (95% CI, 14–40%) for patients who
underwent PCI compared with 14% (95% CI, 0–27%) for
those not receiving PCI. Among the 16 patients who re-
mained alive without disease, 13 received PCI and 11 of
these were in the sequential group. In the multivariate ana-
lysis, improved DFS was only associated with PS 0 group
(RR = 2.44; p = 0.008).
In the univariate analysis (table 3), among the variables
tested, the timing of RT significantly influenced the 3-year
LRC (p = 0.02). At 3 years, the local control rate was 68%
(95% CI, 53–83%) for the sequential group and 42% (95%
CI, 15–69%) for the concurrent group (fig. 3). The re-
sponse to treatment also significantly influenced the 3-year
LRC (43% for PR vs 70% for CR; p = 0.04). A subgroup
analysis was performed to elucidate the differences in out-
comes between patients treated with a median dose of ≥60
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Gy and those treated with a dose of <60 Gy. No statistically
significant differences were found in local control, between
the two groups (p = 0.78). The 3-year LRC was 60% (95%
CI, 39–81%) for patients treated with <60 Gy versus 61%
(95% CI, 44–78%) for those receiving ≥60 Gy. In the mul-
tivariate analysis, improved LRC was associated with se-
quential RT/CT (RR = 1.74; p = 0.02), and complete re-
sponse (RR = 1.76; p = 0.01)
Toxicity
All patients but one received their planned course of RT.
This patient with concomitant rectal cancer refused further
chest radiation after 20 Gy of a planned 60 Gy. He was
treated with supportive care alone. Toxicity was scored ac-
cording to the National Cancer Institute’s Common Ter-
minology Criteria for Adverse Events, version 3.0 [12]. It
was assessable in 61 patients (88%). Details regarding tox-
icity are listed in table 4. The most common grade 3 or
worse toxicity was myelosuppression, followed by naus-
ea, vomiting, pulmonary toxicity, and esophagitis. In gen-
eral, ICE CT tended to cause more febrile neutropenia and
thrombocytopenia than the EP regimen, the latter caus-
ing more nephrotoxicity and neurotoxicity. Of the 69 pa-
tients, 2 (3%) died of treatment-related toxicity (Grade 5).
One death was due to acute herpetic encephalitis second-
ary to late pancytopenia, and the other was related to acute
pneumonia. Six cases of radiation pneumonitis (one grade
3) were observed, as well as 2 cases of mild esophagitis
(grade 2).
Discussion
Optimising the management of patients with LDSCLC
continues to be a challenge. To date, the optimal timing of
chest RT is still controversial. Some studies and meta-ana-
lyses have shown that the early administration of RT, com-
pared to late radiation, may improve significantly the out-
come [13–17] while others have not [1, 18–20]. However,
these studies are difficult to compare given the heterogen-
eity in the therapeutic modalities: RT varied in terms of
total dose [1, 5, 16] and fractionation schemes: convention-
al [1, 18] versus twice-daily regimen [5, 16–17, 21]. Like-
wise, the drugs used in CT, and the dose intensity varied
within previous studies [5, 14].
At present, there is only one prospective study, specifically
addressing the role of concomitant versus sequential CT/
RT in LDSCLC (17). In this study from the Japanese Clin-
ical Oncology Group, 231 patients received 4 cycles of cis-
platin plus etoposide, and were randomly assigned to either
sequential or concurrent twice daily 45-Gy thoracic RT. Al-
Table 3: Univariate analyses (log-rank test) on disease-free survival, overall survival and loco-regional control.
N 3-year
DFS (%)
%95 CI
(%)
p-value p-value* 3-year
OS (%)
%95 CI
(%)
p-value p-value* 3-year
LRC (%)
%95 CI
(%)
p-value p-value*
All patients 69 23 13–33 - - 29 18–40 - - 60 47–73 - -
Age (yrs)
<61 36 22 8–34 0.97 NS 25 11–39 0.80 NS 53 33–83 0.23 NS
≥61 33 24 11–37 33 16–50 68 47–89
PS
0 51 27 16–38 0.004 S 31 20–42 0.06 NS 60 40–80 0.6 NS
1-2 18 12 0–27 25 4–46 49 32–66
Gender
Female 23 32 8–30 0.30 NS 35 15–55 0.5 NS 73 53–93 0.34 NS
Male 46 19 7–31 26 12–40 54 36–72
Clinical T-classification
T1 7 57 21–93 0.47 NS 57 22–92 0.86 NS 100 - 0.17 NS
T2 25 23 3–43 24 4–44 64 41–87
T3 15 14 5–23 32 7–57 33 6–60
T4 22 18 2–34 22 4–40 65 42–88
Clinical N-classification**
N0 8 38 4–72 0.41 NS 37 5–69 0.63 NS 70 35–100 0.07 NS
N1 5 60 18–100 60 20–100 100
N2 37 16 5–27 28 16–44 38 18–58
N3 17 21 2–40 20 0–40 93 79–100
Thoracic RT dose (Gy)
<60 33 21 7–35 0.46 NS 29 13–42 0.52 NS 60 39–81 0.80 NS
≥60 36 25 11–39 30 11–47 62 42–82
Chemotherapy
Sequential 47 27 16–38 0.04 NS 32 18–50 0.21 NS 68 53–83 0.02 NS
Concomitant 22 13 0–28 22 2–42 42 15–69
Response to treatment***
PR 30 11 0–22 0.04 NS 16 2–30 0.04 NS 43 20–66 0.04 NS
CR-nCR 36 29 14–44 35 19–51 70 52–88
PCI
Yes 47 27 14–40 0.03 NS 35 21–49 0.07 NS 67 51–83 0.05 NS
No 22 14 0–27 17 0–34 45 20–70
* Bonferroni correction; NS: not significant; S: significant; RT: radiotherapy; PCI: prophylactic cranial irradiation; DFS: disease-free survival; OS: overall survival; LRC:
locoregional control; ** data missing in 2 patients ; *** data missing in 3 patients; PR: partial response; CR: complete response; nCR: near complete response.
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though the median survival time for patients receiving con-
current therapy was improved compared with patients re-
ceiving sequential treatment (27.2 vs 19.7 months), there
was no statistically significant difference (p = 0.10). In
many centres, patients are still receiving sequential CT/RT
because of initial tumour bulk requiring large fields. In the
present study, the DFS (p = 0.04) but not the OS (p = 0.21)
was significantly better in the group receiving sequential
CT/RT. At 3 years, the LRC was 68% for the sequen-
tial group, and 42% for the concurrent group (p = 0.01).
However, our findings should be carefully interpreted due
to the small sample size and retrospective setting. One ex-
planation for this finding may be related to the heterogen-
eity of CT regimens. In this study, 41% of the patients in
the sequential group received the ICE regimen, while no
patient received the ICE regimen in the concomitant group.
The better DFS in the sequential group can also be ex-
plained by the fact that PCI was delivered more frequently
for the sequential group than the concomitant group (table
2).
Chemotherapeutic regimens have evolved from cyclophos-
phamide, doxorubicin, vincristine (CAV) regimens (22) to
cisplatin–based combinations because of their survival ad-
vantage in limited stage (23), as well as better tolerance in
combination with chest RT. Since the mid 1980s, the cis-
platin and etoposide regimen was considered as the stand-
ard treatment in these patients [6, 21]. This combination
yielded a response rate ranging from 60–90% [6, 24]. The
addition of ifosfamide to EP or CP regimens, called VIP or
ICE, have been tested against the standard EP with mod-
est survival benefits [25–27]. In order to increase the thera-
peutic ratio, some investigators have attempted more in-
tensive chemotherapy, which appears to be very toxic [28].
Moreover, when associated with early concurrent chest RT,
VIP failed to show survival benefits due to higher
treatment-related mortality.
Other agents and chemotherapeutic combinations are also
active. Preliminary data from phase I/II randomised trials
testing the addition of paclitaxel to EP show an improve-
ment in response, and acceptable toxicity in the taxane-
containing arm [29]. However, when this combination was
tested in phase III trials, it was associated with excessive
toxicity and mortality [30].
Nevertheless, paclitaxel was tested in combination with ra-
diation therapy. A phase II study of 38 patients was con-
ducted to assess the feasibility of a combination of paclit-
axel, carboplatin and etoposide, with concurrent involved
field-RT; this demonstrated high response rates and safety.
A 5-year OS of 27% was observed with a very low recur-
rence in the chest despite a total dose of 45 Gy given once
daily [31]. Surprisingly, the rate of brain metastases as the
first site of failure was high (13 out of 19 patients) in this
study.
When addressing the issue of the optimal dose to control
local disease, no study has provided a firm conclusion re-
garding this issue. Since SCLC has been considered an RT-
sensitive disease, modest doses have been used in the range
of 40–50 Gy [1, 14]. A dose-response relationship was sug-
gested by one phase III trial, and two studies from the Mas-
sachusetts General Hospital [32–34]. Doses of 40, 50 and
57 Gy resulted in a local failure rate of 49%, 37%, and 22%
respectively [33]. Turrisi et al. [4] reported dose intensi-
fication for patients with LDSCLC through hyper-fraction-
ated and accelerated RT. In this study, a dose of 45 Gy
twice-daily RT in 3 weeks was compared to 45 Gy daily
fractionated RT starting with the first cycle of cisplatin plus
etoposide CT for the 2 arms. Improved overall survival was
observed in the twice-daily regimen, with a 5-year over-
all survival rate of 26% versus 16% for the once-daily re-
gimen. The local control rate was 64% for the twice-daily
arm versus 48% for the once-daily schedule. However,
a higher rate of grade 3 or 4 esophagitis was observed with
the twice-daily schedule (27% vs 11%). Conversely, Bon-
ner et al. [35] compared a split-course hyper-fractionated
RT to conventional RT, and did not find any survival be-
nefit with RT starting at the fourth or fifth cycle of CT.
Moreover, a split-course regimen was used in the hyper-
fractionated group, which is considered to probably have
an unfavourable biological effect. Thus, the benefit found
by the Eastern Cooperative Oncology Group [35] seems to
be related to the dose intensity of hyper-fractionation and
CT rather than hyper-fractionation alone. However, when
deciding which dose and fractionation to deliver, clinicians
are reluctant to use the twice-daily regimen, since it is not
only associated with high toxicity but is also inconveni-
ent for daily RT practice. Dose escalation of daily frac-
Table 4: Acute and late toxicity in *patients with small cell lung cancer treated with chemoradiation (CTCAE v3.0 classification).
Toxicity Grade 0–2 Grade 3 Grade 4 Total % of total
Acute
Febrile neutopenia - 17 4 21 34
Leukopenia 5 3 1 9 15
Anaemia 12 5 1 18 29
Thrombocytopenia 1 1 5 7 11
Dysphagia 5 0 0 5 8
Neuropathy 6 1 3 10 16
Nephropathy 6 1 0 7 11
Nausea-vomiting 12 4 0 16 26
Ototoxicity 2 0 0 2 3
Late
Pneumonitis 5 1 0 6 9
Esophagitis 2 0 0 2 3
Leucoencephalopathy 2 0 0 2 3
Memory impairment 0 2 0 2 3
* no toxicity data were available in 8 patients; CTCAE: Common Terminology Criteria for Adverse Events
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tionated RT is another method of dose intensification. A
conventional fractionation schema is chosen with higher
total dose, at least biologically equivalent to the 45 Gy.
In 1998, Choi et al. [36] reported a dose-escalation phase I
radiotherapy trial. Patients were either treated with conven-
tional thoracic irradiation or twice-daily fractionation. The
maximum-tolerated dose of radiation was determined to be
70 Gy (in 35 fractions of 2 Gy) for daily RT. Likewise,
Bogart et al. [37] reported results of a phase II, dose es-
calation, multi-institutional, prospective trial. In this study,
the total dose was 70 Gy delivered once-daily with con-
current carboplatin/etoposide CT following induction CT
with paclitaxel and topotecan. Such dose escalation pro-
duced acceptable toxicity with 16% reported grade 3 tox-
icity. Moreover, the 2-year overall survival and failure-
free survival rates were 48% and 31%, respectively. In our
present study, the median radiation dose was 60 Gy, and
there was no difference in terms of outcome between pa-
tients receiving doses of 60 Gy or more and patients receiv-
ing 60 Gy or less.
In LDSCLC, a meta-analysis of studies assessing the use
of PCI revealed an absolute survival benefit of 5.4% at
3-years favouring PCI in patients achieving a complete re-
mission [4]. The 3-year survival rate was 15.3% in the con-
trol group versus 20.7% in the treatment group. However, a
number of patients still refuse this treatment because of the
risk of neuro-cognitive function alteration. In the present
series, 47 patients (68%) received PCI. Improved DFS was
observed in patients receiving PCI (p = 0.03). Moreover, a
trend toward improved survival was observed for patients
who underwent PCI (p = 0.07). The 3-year OS was 35% for
patients who underwent PCI compared with 17% for those
not receiving PCI. Furthermore, PCI was recently recom-
mended even for patients with extensive SCLC [38], where
a clear advantage of PCI was found with respect to the in-
cidence of symptomatic metastases. A survival advantage
was also found.
In summary, in this study no RT dose-response relationship
was observed. Complete response to treatment seems to be
the most important factor for survival and local control. A
better DFS was significantly associated with PCI group.
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